Palo Alto, CA – Vivo Capital, a healthcare investment firm with offices in Palo Alto, Beijing, Shanghai, and Taipei, announced the final closing of Vivo Opportunity Fund, L.P. (the “Fund”) at an oversubscribed $635 million, which brings the firm’s total funds under management to more than $2.2 billion.
As a long-only public equity fund, the Fund plans to invest the capital in small to mid-cap public life sciences companies through follow-on financings, private placements, initial public offerings and block trades. Vivo intends to leverage its deep sector experience and fundamentals-driven approach from its prior funds that have invested in private and public therapeutics companies. The Fund is focused on investing in companies bringing innovative products to the market.
Investors in the Fund include financial institutions, pension funds, endowments, foundations, and family offices.
About Vivo Capital
Founded in 1996, Vivo Capital is a healthcare investment firm focused on investing in and building high quality companies around the world. With more than $2.2 billion under management across multiple funds, Vivo Capital employs a unique multi-pronged strategy of identifying and working with companies that are developing and commercializing products and technology. Vivo Capital (http://www.vivocapital.com/) has offices in Palo Alto, Beijing, Shanghai and Taipei.